AX-2026-043630 · Ipamorelin · WXT lot WXT-2510-B5567

Section 1

Results

Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	98.60	% area	≥ 99.0	FAIL
Total impurities	RP-HPLC, sum of reported peaks	1.40	% area	≤ 1.0	FAIL
Largest single impurity	RP-HPLC — des-Lys (−128 Da)	0.97	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	711.3856	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	711.3874	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+2.6	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	3.65	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	7.28	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.28	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White to pale-yellow cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear with a single visible fibre	—	clear, no visible particulates	FAIL
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	6.06	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	8.27	min	8.24 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.06	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	74,558	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Trp]-epimer	0.97	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 74,558, and skew follows the reported asymmetry factor of 1.06. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.97 % impurity against a 98.60 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Ipamorelin — main peak	8.27	4,792,266	98.60	—
2	des-Lys (−128 Da)	8.05	47,145	0.97	-128.095
3	oxidised Trp (+16 Da)	7.93	12,151	0.25	+15.995
4	[D-Trp]-epimer	8.15	4,860	0.10	0.000
5	Aib-deletion sequence (−85 Da)	7.99	2,430	0.05	-85.053
6	C-terminal free acid (+1 Da)	8.45	1,458	0.03	+0.984
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 711.3856 Da, computed from C38H49N9O5. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 711.3874 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
2+	356.7001	356.7010	0.0009	53.1
1+	712.3929	712.3947	0.0018	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.04	98.60	divergence -0.47 pp vs batch median
Total impurities (% area)	1.96	1.40
Largest single impurity (% area)	not stated	0.97
Water (%)	2.7	3.65
Counter-ion (%)	not stated	7.28
Peptide content (%w/w)	92.5	not determined
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Supplier-supplied
Evidentiary weight: Weaker evidence. Read with the caveat below.
Chain of custody: Supplier despatch → laboratory direct (courier, cold pack, 3 d) → assay. Submitter did not handle the vial.
Assay date: 10 Dec 2025
Submitted to the index: 04 Jan 2026
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

multiple_compare04 Jan 2026

Sixty-six compounds and twenty suppliers is a lot of cells. Some records will sit below specification by chance alone, and a single one is not a supplier finding. The per-compound table on the scorecard is the correct denominator.

mass_defect04 Jan 2026

Identity confirmed, purity 98.60 %, mass balance closed. This record is complete against the index definition of complete and there is nothing outstanding on it.

survivor_lots04 Jan 2026

A supplier sending a sample chooses a lot as well as a vial. Both selections point the same way and neither is separable from the other in a single record.

Section 7

Related records

Same batch — lot WXT-2510-B5567 n=9

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2025-021229	WXT-2510-B5567	Janoshik	2025-Q4	99.21	4.05	106.3	Supplier-supplied	PASS
AX-2025-021230	WXT-2510-B5567	VendorInvestigate	2025-Q4	98.90	3.87	—	Buyer-sourced	FAIL
AX-2025-021231	WXT-2510-B5567	Janoshik	2025-Q4	98.38	3.14	—	Supplier-supplied	FAIL
AX-2025-021232	WXT-2510-B5567	Janoshik	2025-Q4	98.36	3.72	—	Buyer-sourced	FAIL
AX-2025-021233	WXT-2510-B5567	PeptideMeter	2025-Q4	98.58	3.76	99.1	Buyer-sourced	FAIL
AX-2025-021234	WXT-2510-B5567	Janoshik	2025-Q4	98.51	3.54	94.8	Buyer-sourced	FAIL
AX-2025-021235	WXT-2510-B5567	Janoshik	2025-Q4	98.05	3.35	94.9	Buyer-sourced	FAIL
AX-2025-021236	WXT-2510-B5567	Janoshik	2025-Q4	98.08	3.88	93.8	Buyer-sourced	FAIL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Ipamorelin records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042346	Homopeptide	HOMO-2608-A2117	Medutest	2026-Q3	99.06	5.05	—	Buyer-sourced	0	PASS
AX-2026-042347	Homopeptide	HOMO-2608-A2117	Medutest	2026-Q3	99.79	4.90	—	Buyer-sourced	0	PASS
AX-2026-041411	QYB	QYB-2605-H4076	Janoshik	2026-Q3	99.86	3.59	90.6	Buyer-sourced	0	PASS
AX-2026-041410	QYB	QYB-2605-H4076	Medutest	2026-Q3	99.87	4.58	101.5	Laboratory-retained	1	FAIL
AX-2026-042351	Homopeptide	HOMO-2608-A2117	VendorInvestigate	2026-Q3	99.15	5.02	100.1	Buyer-sourced	0	PASS
AX-2026-041408	QYB	QYB-2605-H4076	Kestrel	2026-Q3	99.93	4.49	—	Buyer-sourced	1	FAIL
AX-2026-042350	Homopeptide	HOMO-2608-A2117	Kestrel	2026-Q3	99.93	4.74	92.5	Laboratory-retained	0	PASS
AX-2026-043245	KP	KP-2606-D6960	PeptideMeter	2026-Q3	99.25	3.42	—	Buyer-sourced	0	PASS

Other recent WXT records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043651	Pramlintide	WXT-2603-D6459	PeptideMeter	2026-Q3	98.21	4.97	101.6	Buyer-sourced	1	MARGINAL
AX-2026-043531	Leuprolide	WXT-2604-K4483	Medutest	2026-Q3	99.00	5.03	—	Buyer-sourced	0	PASS
AX-2026-043561	Semaglutide	WXT-2604-C5135	Janoshik	2026-Q3	96.96	4.22	91.3	Buyer-sourced	0	FAIL
AX-2026-043627	L-Glutathione (reduced)	WXT-2605-B5720	Janoshik	2026-Q3	97.96	6.08	92.3	Buyer-sourced	1	FAIL
AX-2026-043564	Semaglutide	WXT-2604-C5135	Janoshik	2026-Q3	97.15	4.44	104.7	Buyer-sourced	0	PASS
AX-2026-043533	Leuprolide	WXT-2604-K4483	PeptideMeter	2026-Q3	99.89	4.94	—	Supplier-supplied	0	PASS
AX-2026-043624	L-Glutathione (reduced)	WXT-2605-B5720	Nordanalyt	2026-Q3	98.18	6.95	105.3	Buyer-sourced	2	FAIL
AX-2026-043556	Semaglutide	WXT-2604-C5135	PeptideMeter	2026-Q3	97.56	4.35	89.6	Buyer-sourced	1	MARGINAL